Close

News

Symbiosis confirms commitment to growth strategy with key appointment

Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, and headquartered in Stirling, UK, has appointed Mr. John McCormick as chief operating officer (COO) and executive member of its...

Europital forecast 30% CAGR from UK biotech for three years

Europital – the global provider of medical management services for clinical research and drug development – announces it is opening a UK site to further expand its services to the UK biotech industry. The company is already working with...

Informa Markets in India all set to host the 9th edition of InnoPack Pharma Confex, virtually this year

CPhI Conferences India, a division of Informa Markets in India, which hosts a number of successful pharmaceutical conferences, has announced the 9th Annual InnoPack Pharma Confex slated for 3rd and 4th September 2020, this year in a virtual format....

Perigord becomes the most certified supplier of artwork solutions to the Life Science industry

Perigord confirms, that in achieving its latest certification ISO 27001, that they are the only Global provider of Artwork Management Systems (AMS) to the Life Science industry to be certified by BSI to ISO 27001, ISO 9001 and PS...

Clinerion protects security of Patient Network Explorer user accounts with 2-step authentication

The “Clinerion PNEx Authenticator” app gives users of Clinerion’s Patient Network Explorer additional data security with 2-step authentication. To protect Patient Network Explorer user accounts from breach, Clinerion is activating a second verification step during the sign-in process. In addition...

Evotec and Novo Nordisk form strategic alliance to develop novel therapies for kidney diseases

Evotec SE and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease. Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular...

BMS and Dragonfly Therapeutics Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

Bristol Myers Squibb and Dragonfly Therapeutics, Inc. announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read